Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2426-0266
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease ; day:7 ; month:4 ; year:2021 ; pages:1-9
The journal of prevention of Alzheimer's disease ; (7.4.2021), 1-9
- Creator
-
Kellar, D.
Lockhart, S. N.
Aisen, P.
Raman, R.
Rissman, R. A.
Brewer, J.
Craft, Suzanne
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.14283/jpad.2021.14
- URN
-
urn:nbn:de:101:1-2021060118450580974399
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:43 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kellar, D.
- Lockhart, S. N.
- Aisen, P.
- Raman, R.
- Rissman, R. A.
- Brewer, J.
- Craft, Suzanne
- SpringerLink (Online service)
Other Objects (12)
Intranasal Insulin for Alzheimer’s Disease
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Brainstem substructures and cognition in prodromal Alzheimer’s disease
Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer’s mice
CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Intranasal Insulin for Alzheimer’s Disease
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Brainstem substructures and cognition in prodromal Alzheimer’s disease
Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer’s mice
CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Intranasal Insulin for Alzheimer’s Disease
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
CSF Presenilin-1 complexes are increased in Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Brainstem substructures and cognition in prodromal Alzheimer’s disease
Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer’s mice
CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
Dynamic changes of CSF clusterin levels across the Alzheimer’s disease continuum
Disease staging of Alzheimer’s disease using a CSF-based biomarker model